Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensitizing Potential of BAY H006689 (Naproxen 10% Gel) in Healthy Subjects
NCT06415019Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of naproxen in myalgia and arthralgia (3 arms), sponsored by Bayer. Primary endpoint: Skin sensitization potential up to 12 weeks. Started Jun 2024; status: completed.
02
Drugs
naproxen
03
Conditions
myalgiaarthralgia
Beyond the preview
Go deeper on NCT06415019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415019.